PMID- 33432090
OWN - NLM
STAT- MEDLINE
DCOM- 20210826
LR  - 20231104
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jan 11
TI  - Comparison of visual outcomes between therapy choices and subtypes of polypoidal 
      choroidal vasculopathy (PCV) in Taiwan: a real-world study.
PG  - 470
LID - 10.1038/s41598-020-80731-1 [doi]
LID - 470
AB  - Polypoidal choroidal vasculopathy (PCV) is a distinctive type of neovascular 
      age-related macular degeneration prevalent in many Asian countries. However, 
      there is still some controversy in how the subtypes of PCV are classified. This 
      post-hoc study redefined the branching vascular network (BVN) and PCV subtypes 
      through retrospective review of indocyanine green angiography (ICGA) and 
      fluorescein angiography images from two observational studies (RENOWNED/REAL). Of 
      the visual outcomes for each angiographic subtype and treatment pattern 
      investigated, BVN was identified in 56.3% of PCV patients. The proportions and 
      features of the re-defined PCV subtypes were 43.8%, 10.4%, and 45.8% for subtype 
      A (without distinctive features of BVN), B (with BVN but no leakage), and C (with 
      BVN and leakage), respectively. Subtype A had better visual outcomes when 
      compared to subtype C. This possibly resulted from a better baseline visual 
      acuity in subtype A. Moreover, combination therapy [photodynamic therapy plus 
      anti-vascular endothelial growth factor (VEGF)] may lead to better visual 
      improvement than mono-anti-VEGF treatment alone. This study provides the 
      prevalence of PCV subtypes in Taiwan and may serve as a reference for PCV 
      treatment strategies in a real-world setting, especially for the combination 
      therapy and patients without distinctive features of BVN.
FAU - Yeung, Ling
AU  - Yeung L
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Keelung City, 
      Taiwan.
FAU - Lai, Chi-Chun
AU  - Lai CC
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Keelung City, 
      Taiwan.
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taoyuan City, 
      Taiwan.
FAU - Chen, San-Ni
AU  - Chen SN
AD  - Department of Ophthalmology, Changhua Christian Hospital, Changhua City, Taiwan.
FAU - Cheng, Cheng-Kuo
AU  - Cheng CK
AD  - Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Shilin 
      District, Taipei City, Taiwan.
FAU - Yang, Chung-May
AU  - Yang CM
AD  - Department of Ophthalmology, School of Medicine, National Taiwan University 
      Hospital, No. 7, Zhongshan South Road, Zhongzheng District, Taipei City, 100, 
      Taiwan.
FAU - Hsieh, Yi-Ting
AU  - Hsieh YT
AD  - Department of Ophthalmology, School of Medicine, National Taiwan University 
      Hospital, No. 7, Zhongshan South Road, Zhongzheng District, Taipei City, 100, 
      Taiwan.
FAU - Tsai, Arslan
AU  - Tsai A
AD  - Clinical Development and Medical Affairs, Novartis Taiwan, Taipei City, Taiwan.
FAU - Yang, Chang-Hao
AU  - Yang CH
AD  - Department of Ophthalmology, School of Medicine, National Taiwan University 
      Hospital, No. 7, Zhongshan South Road, Zhongzheng District, Taipei City, 100, 
      Taiwan. chyangoph@ntu.edu.tw.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210111
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
MH  - Aged
MH  - Choroidal Neovascularization/classification/diagnostic 
      imaging/epidemiology/*therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Indocyanine Green
MH  - Macular Degeneration/classification/diagnostic imaging/epidemiology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Photochemotherapy/*methods
MH  - Prevalence
MH  - Taiwan/epidemiology
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*administration & dosage
PMC - PMC7801625
COIS- The authors declare no competing interests.
EDAT- 2021/01/13 06:00
MHDA- 2021/08/27 06:00
PMCR- 2021/01/11
CRDT- 2021/01/12 06:06
PHST- 2020/08/28 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/12 06:06 [entrez]
PHST- 2021/01/13 06:00 [pubmed]
PHST- 2021/08/27 06:00 [medline]
PHST- 2021/01/11 00:00 [pmc-release]
AID - 10.1038/s41598-020-80731-1 [pii]
AID - 80731 [pii]
AID - 10.1038/s41598-020-80731-1 [doi]
PST - epublish
SO  - Sci Rep. 2021 Jan 11;11(1):470. doi: 10.1038/s41598-020-80731-1.